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Natural and accelerated vascular aging. 
Involved mechanisms and factors 
The vascular aging process 
In 2006, Dzau et al. presented the cardiovascular disease 
(CVD) continuum, represented by successive events/stages of 
disease progression from the incidence of known risk factors 
until death.1 This whole concept had the genesis and progression 
of atherosclerosis as its nuclear mechanism of progression to 
underlying CVD. In 2010, Dzau et al. gave new emphasis to the 
importance of age-related structural changes in the middle layer 
of the arterial wall (arteriosclerosis) as a contributing mechanism 
for the risk of development of CVD.2
There is a natural process of wear and progressive modification 
of the arterial wall structure that arises from the mechanical stress 
of distension induced at each cardiac cycle in connection with 
the pulse wave amplitude and incident and reflex pressure.3 
In the absence of any other factor, this mechanism alone will 
produce wear on the arterial wall, promoting thickness reduction, 
fragmentation, and disorganization of the elastin layers. In 
parallel, this damaged elastic component is replaced by collagen 
and protein matrix, which is less capable of accommodating 
the incident pulse wave pressure. In addition, there is loss of 
integrative and functional connection between elastin layers and 
smooth muscle vascular cells,4 resulting in reduced distensibility 
and increased stiffness of the large artery wall, which can be 
measured by an increase in the transmission of the pulse wave 
velocity (PWV) and the return of the reflex wave. Thus, there is 
an influence on the central systolic blood pressure (cSBP), central 
pulse pressure, “augmentation index”, and other ventricular-
vascular integration indices.5
The factors accelerating arterial aging are multiple: fetal 
programming, genetic factors, hypertension, dyslipidemias, 
diabetes mellitus, chronic renal disease, chronic diseases with an 
inflammatory component, and smoking, among others. 
Accelerated vascular aging
The identification of individuals with accelerated vascular 
aging may allow an earlier specific intervention, with 
control of the various risk factors. For each carotid-femoral 
PWV (cfPWV) increase of 1 m/s, the risk of cardiovascular 
death, cardiovascular event, or mortality from other causes 
increases between 14 and 15%.6 The publication of cfPWV7 
reference values for different age groups has allowed an easier 
identification of individuals with early signs of arterial stiffness. 
However, ethnic and/or environmental exposure aspects that 
may also contribute to the arterial aging process should be 
taken into account in the definition of “normal”.8
Arterial aging: relationship between microcirculation 
and macrocirculation, and between arteriosclerosis 
and atherosclerosis
We can identify four key milestones in the vascular aging 
process: 1) a progressive reduction in the distensibility of large 
muscular arteries; 2) a progressive increase in the reflected 
pressure wave, with a consequent increase in the various 
components of central arterial pressure; 3) a loss of the arterial 
stiffness gradient between the central and peripheral arteries; 
and 4) a progressive elimination of the impedance differential 
between the arterial macrocirculation and microcirculation.9-11 
This set of structural and functional changes in the arterial 
tree following the deterioration of the structure and function 
of the middle layer of the arterial wall (arteriosclerosis) is 
associated with the appearance and concomitant development 
of atherosclerosis lesions in the vessel wall, having endothelial 
dysfunction as a unifying mechanism.12
Measures of Central and Peripheral 
Pressures: Differences and Advantages
Brachial blood pressure (BP) measured with a 
sphygmomanometer cannot be considered equivalent to 
aortic pressure since the latter has invariably lower values. 
The BP varies continuously during the cardiac cycle, although 
in practice only the maximum value during systole and the 
minimum value during diastole are measured. Furthermore, 
the shape of the pulse wave varies along the arterial tree. 
With the advancement of the pulse wave from the more 
elastic central arteries to the more rigid peripheral arteries, the 
systolic peak becomes narrower and more elevated (Figure 
1). Considering that the diastolic BP (DBP) and the mean BP 
are relatively constant, the brachial systolic BP (SBP) can be 
30 mmHg higher than the central systolic aortic pressure in 
young individuals. This phenomenon, known as amplification 
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Figure 1 – Amplification of systolic pressure from central to peripheral arteries.
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of systolic pressure (or pulse pressure), occurs due to several 
reasons, among them the smaller caliber and greater stiffness 
of the peripheral arteries. In addition, pulse wave reflections 
occur at several sites in the arterial network, such as areas with 
greater collagen/elastin gradient, with greater vasomotor tone 
and, especially, at bifurcation points. Multiple reflected pulse 
waves integrate into a single reflected wave that is added to the 
incident pulse wave, caused by the ventricular ejection. When 
the reflected wave reaches the incident wave earlier, there is 
an increase in the central systolic pressure and, consequently, a 
reduction in the amplification of the pulse pressure. In fact, this 
increase in pressure depends on several variables, especially age, 
gender, height, and heart rate.13-15 Female gender, advanced 
age, short stature, and bradycardia are associated with a 
lower pulse pressure amplification. Even with the control of 
these variables, only about 70% of the variability in the pulse 
pressure amplification can be explained in multiple regression 
models.13,16 This indicates that central pressure cannot be 
accurately estimated from the brachial pressure using statistical 
models, but it actually needs to be determined directly through 
appropriate methods.
Advantages
Measurement of central pressure could result in greater 
accuracy in the diagnosis of hypertension, greater safety in the 
therapeutic decision, and better definition of the prognosis.17,18 
Some authors have identified that central pressure, compared 
with brachial pressure, correlates better with intermediate 
cardiovascular risk markers such as carotid intima-media 
thickness and left ventricular hypertrophy.19,20 Several studies 
have reported an independent relationship between central 
pressure and future cardiovascular events, including in 
elderly patients with coronary disease and chronic kidney 
disease.14,21-23 However, other studies have not found a superior 
predictive value for central pressure over brachial pressure.24 
This controversy exists because the methodology is still 
heterogeneous and the peripheral pressure, necessary for the 
final result, explains more than 90% of the variation in central 
pressure. Furthermore, derivation of central pressure requires 
an additional measurement, usually radial tonometry, which 
is also subject to errors that may contribute to the remaining 
10% of the variation.18 Therefore, before recommending central 
pressure measurement for wide clinical use, standardization of 
the method and the calibration system, and technical limitations 
of the various devices available must be resolved.
Definition, evaluation and normal values 
of the main central parameters (central 
aortic pressure and carotid-femoral pulse 
wave velocity)
The SBP values vary considerably according to the place 
where they are obtained. The SBP is greater in the brachial 
artery when compared with the aorta. This difference in 
pressure values between the aorta and the brachial artery is a 
consequence of the phenomenon of peripheral amplification, 
which results from the difference in impedance between 
the large-, medium- and small-caliber arteries, especially 
in the bifurcations, and also the presence of several factors 
of interference, such as age, comorbidities (dyslipidemia, 
smoking, diabetes mellitus, etc.) and environmental factors 
(sodium).25 Recent evidence indicates that central aortic 
pressure, the augmentation index, and cfPWV are robust 
markers for future cardiovascular events.21,26
An important aspect in relation to central systolic 
pressure concerns pressure values obtained with commercial 
equipment by noninvasive methods. Although these values 
correlate well with invasive studies, they do not fully represent 
the central systolic pressure values, but they correctly reflect 
the amplification phenomenon. This static measurement is 
considered insufficient for a definitive validation of these 
methods in the stratification of cardiovascular risk.27
Measurement of cfPWV is an appropriate method of 
assessing arterial aging with an excellent correlation with 
the risk of cardiovascular death, cardiovascular events, and 
mortality from other causes.6 The stiffening of the distal aorta 
and large arteries, such as the carotid and iliac arteries, occurs 
due to the early return of the reflection wave, secondary to 
structural and functional alterations of the distal vascular wall. 
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Therefore, the great arteries differ from medium and 
small arteries in relation to histology, physiology, and elastic 
properties, which is why it is extremely important to define the 
anatomical target for the action of a drug and the therapeutic 
target to be achieved. Evidence regarding drug treatment 
points to a greater ease of reversal of alterations in small-caliber 
arteries (muscle) than in large arteries (elastic). Thus, results 
obtained in one arterial segment cannot be extrapolated to 
other segments in the same arterial tree. Tables 1 and 2 show 
the central aortic systolic pressure, augmentation index, and 
cfPWV values in the normal population.28,29
Evaluation methodology - available devices 
and their validations
The cfPWV, which directly reflects arterial stiffness, has a 
predictive value in cardiovascular morbidity and mortality and 
is currently considered the gold standard method to assess 
arterial stiffness.5
The devices used to measure cfPWV have evolved over 
the last two decades, and their new versions have received 
systematic validation. Numerous studies have been published 
comparing invasive and noninvasive methods in different 
populations and among several existing noninvasive cfPWV 
measurement devices such as oscillometric, piezoelectric, 
and tonometric. Most of them have a good correlation with 
the methods most used in epidemiological studies, such as 
Complior® or SphymoCor®, among others. Currently, these 
methods involve little operator training and the ease of use 
and time consumed in the exam have been optimized so that 
they are becoming more available for use in clinical practice 
with good intraobserver and interobserver correlations.30
Some differences have been found in studies comparing 
devices, with higher values  of systematically hemodynamic 
parameters obtained with one device in particular. 
The mathematical models used in different devices can lead to 
different results. However, in most cases, this has no translation 
in clinical practice, since it does not imply a change in the risk 
class of the individual. Nevertheless, it is prudent that the same 
type of equipment is used in multicenter research studies.31 
In addition to the validation of different equipment, 
different procedures for measuring cfPWV have also 
been proposed. These different procedures, such as 
measuring the carotid-femoral distance, can influence 
the results obtained if they are not also standardized. 
In this case, there are arguments that 80% of the direct 
carotid-femoral distance is the most accurate estimate for 
this same distance.5 
Table 2 – Carotid-femoral pulse wave velocity values (m/s) in normal individuals29
Age Mean ± 2SD Median (percentile 10 – 90)
<30 a 6.6 (4.9 – 8.2) 6.4 (5.7 – 7.5)
30 – 39 a 6.8 (4.2 – 9.4) 6.7 (5.3 – 8.2)
40 – 49 a 7.5 (5.1 – 10.0) 7.4 (6.2 – 9.0)
50 – 59 a 8.4 (5.1 – 11.7) 8.1 (6.7 – 10.4)
60 – 69 a 9.7 (5.7 –13.6) 9.3 (7.6 – 12.1)
> 70 a 11.7 (6.0 – 17.5) 11.1 (8.6 – 15.5)
SD: standard deviation.
Table 1 – Central systolic aortic pressure values and the augmentation index in normal individuals28
Central aortic pressure (mmHg) Augmentation index (%)
Female Male Female Male
Age (years) Mean Percentile (10–90) Mean
Percentile 
(10–90) Mean
Percentile 
(10–90) Mean
Percentile 
(10–90)
<20 97 86 –109 105 96 – 113 14 9 – 20 19 11 – 24
20 – 29 95 80 – 110 103 92 – 115 12 5 – 19 15 6 – 24
30 – 39 98 84 – 119 103 88 – 120 8 0 – 17 13 4 – 23
40 – 49 102 87 – 123 106 90 – 123 6 0 – 15 11 2 – 21
50 – 59 110 93 – 127 110 96 – 126 5 0 – 13 9 2 – 18
60 – 69 114 97 – 129 114 97 – 128 6 1 – 12 8 2 – 17
> 70 118 100 – 131 116 99 – 130 6 1 – 13 8 1 – 17
% = percentage increase.
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Central parameters: differences according 
to age, sex, and ethnicity
The best way to define normal values for central aortic 
pressure would be a correlation between the central aortic 
pressure levels obtained and the cardiovascular risk, as 
known for the BP obtained by the conventional or brachial 
method. However, these data are not yet available as results 
of prospective studies designed for this specific purpose, 
although some publications have sought to obtain these 
correlations between cardiovascular outcomes and central 
aortic pressure.21 
One strategy would be to obtain correlations between 
central aortic pressure values that correspond to conventional 
pressure values obtained in the casual brachial artery or in the 
clinic. Following this strategy, population studies suggest that an 
optimal systolic central aortic pressure would be represented by 
values < 110 mmHg, which would be equivalent to 120 mmHg 
when obtained by the conventional BP measurement. Likewise, 
a central aortic pressure < 120 mmHg would correspond to a 
brachial SBP of 140 mmHg, defining as stage 1 systemic arterial 
hypertension a systolic central aortic pressure ≤ 120 mmHg.32
Applicability and cost-benefit relationship of 
the measurement of central parameters
Although it is not part of the stratification routine in 
hypertensive patients, the central aortic pressure has 
attracted increasing interest due to its predictive value for 
the occurrence of cardiovascular events, as well as for the 
differential evaluation of the different anti-hypertensive 
drugs, when compared with the traditional determination 
of the brachial pressure.33 The augmentation index and 
the pulse pressure measured by carotid tonometry have 
been considered independent predictors of cardiovascular 
mortality in end-stage renal disease. However, the predictive 
value of the central aortic pressure, when compared with 
that of the brachial BP showed no significant differences.21 
Nevertheless, the recommendation for its routine use 
requires further studies. As an exception and as an added 
value, isolated systolic hypertension is observed in youths, 
since the brachial artery SBP in these individuals may be 
increased due to an exaggerated amplification of the central 
pressure wave, which would be normal.34
There are no data verifying the cost-benefit relationship 
of central aortic pressure determination, extrapolating it from 
small studies with the use of angiotensin II receptor blocker 
(e.g., losartan), which reduces central aortic pressure and may 
bring some additional benefit when using it in addition to the 
reduction of brachial BP.35
Isolated systolic hypertension in young 
adults: true hypertension and spurious 
hypertension
The pathophysiological mechanism of isolated systolic 
hypertension in elderly and young individuals is not the 
same. In addition, information on the prognosis of both is 
scarce and the guidelines currently available offer different 
recommendations on how to address these situations 
depending on the age group.34
Isolated systolic hypertension in young adults (ISHY) 
was described in 1999 as a “spurious” elevation of the 
SBP or pseudo-elevation of the SBP (> 140 mmHg) with 
normal values  of diastolic pressure (< 90 mmHg) resulting 
from a phenomenon of amplification of the peripheral 
arterial pulse waveform.36 ISHY is more common in male 
athletes, in individuals who are taller, and in those with 
higher body mass index.37 The prevalence of ISHY shows a 
significant variation (between 2% and 16%) in exclusively 
male cohorts and has obesity and tobacco as two of the 
main determinants.38 The noninvasive evaluation of the 
central pressure and pulse wave amplification in the upper 
limbs has a precise indication in these cases, since it allows 
the identification of young adults with “spurious” isolated 
systolic hypertension, sparing them from being labeled as 
“hypertensive patients”.39 The identification of patients with 
ISHY should be complemented by outpatient monitoring to 
exclude white coat hypertension.40
ISHY has increased in prevalence and, given the lack of 
information about it, there are controversies about how to 
intervene in this situation. If on the one hand the values of 
central aortic pressure in individuals with ISHY are lower than 
those found in true hypertensive patients, they are higher than 
those obtained in normotensive patients.39 The study by Yano 
et al.,41 of 2015, showed a higher cardiovascular risk in this 
group when compared with individuals with optimal BP, but 
the study did not include an assessment of the central pressure 
for a possible differentiation between the groups.41 With the 
information available, the management is to carefully monitor 
with nonpharmacological measures, with a more aggressive 
management reserved for situations of greater associated 
cardiovascular risk, at least until new data are available.42
Prognostic value of the ambulatory arterial 
stiffness index 
The ambulatory arterial stiffness index (AASI) is used for 
the evaluation of arterial stiffness and is calculated based 
on the slope of the diastolic pressure versus the values from 
the systolic pressure in outpatient monitoring, evaluating 
the dynamic relationship between the DBP and the SBP in 
24 hours.43 
Thus, for any increase in the distension of the artery 
wall, the SBP and DBP values tend to increase in parallel, 
whereas in a rigid artery, there is an increase in the value of 
SBP accompanied by a lower elevation or even a decrease in 
DBP. Li et al.44 confirmed in a healthy Chinese population that 
there was a significant correlation coefficient between AASI 
and cfPWV, which is the gold standard method.44
The AASI depends on the degree of functional and 
structural integrity of the arteries, and may also depend on the 
ejected systolic volume and the reflection waves.45
Because the AASI is dependent on the mechanical 
properties of small arteries and reflection waves, this index 
correlates well with pulse pressure and augmentation index, 
103
Special Article
Brandão et al
I Luso-Brazilian positioning on central arterial pressure
Arq Bras Cardiol. 2017; 108(2):100-108
and has a good correlation with some markers of lesion in 
target organs (ventricular hypertrophy, carotid lesion, and 
microalbuminuria).46
Some studies have shown a relationship between AASI and 
global and cardiovascular mortality, as well as a relationship 
with stroke in normotensive individuals.47 Nevertheless, this 
prognostic value is still debatable and is related to the degree of 
decrease during sleep and other factors, such as heart rate and 
peripheral vascular resistance.48 Moreover, its reproducibility 
is poor (around 50-68%).49
Central parameters as predictors of arterial 
hypertension
There is evidence that increased arterial stiffness is 
a precursor to the occurrence of hypertension and not 
a consequence of increased BP. The increase in cfPWV 
preceded the appearance of hypertension over 7 years in 
an analysis of the Framingham Heart Study.50 The Baltimore 
Longitudinal Study of Aging also demonstrated an association 
between increased cfPWV and a higher incidence of 
hypertension.51 Other central parameters emerged as 
predictors of hypertension, such as increased brachial-ankle 
pulse wave velocity, increased proximal aortic stiffness assessed 
by echocardiography, and increased carotid artery stiffness, 
as demonstrated in the Atherosclerosis Risk in Communities 
(ARIC) study.52-54
The increase in aortic stiffness correlated with a lower 
sensitivity of the baroreflex, a precursor mechanism for the 
development of hypertension, as well as an increase in the 
BP variability.55,56 
Central parameters and cardiovascular risk
Role of the carotid-femoral pulse wave velocity as a 
predictor of cardiovascular outcomes 
The cfPWV is the most studied central parameter; 
consequently, there is a greater amount of evidence related 
to this parameter. Thus, it has been demonstrated that the 
cfPWV has an independent predictive value for different 
cardiovascular outcomes in different subgroups, as in 
patients with hypertension, type 2 diabetes, elderly and 
in those with end-stage renal disease.57 Even in apparently 
healthy individuals, cfPWV is an independent predictor of 
coronary disease and stroke.58,59 When the predictive values 
for cfPWV and peripheral pressure have been compared, 
the cfPWV showed an infallible superiority.60 A systematic 
review including 16 studies with 17,635 participants revealed 
that for each increase of one standard deviation in cfPWV, 
the risk ratio was 1.35 (95% confidence interval [95%CI] 
1.22 – 1.50, p < 0.001) for coronary disease, 1.54 (95%CI, 
1.34 – 1.78, p < 0.001) for stroke, and 1.45 (95%CI, 
1.30 – 1.61, p < 0.001) for cardiovascular disease. These 
risk ratios were even higher in younger participants and 
remained significant even after adjustment for the presence 
of conventional cardiovascular risk factors.59 
Small studies have shown that the persistent elevation of 
pulse wave velocity during the treatment of hypertension 
or cardiovascular disease is associated with a high risk for a 
cardiovascular event.60 
Role of the carotid-femoral pulse wave velocity in the 
stratification of cardiovascular risk
Studies have shown that the addition of cfPWV to 
traditional risk factors involved in scores such as Framingham 
and SCORE, and even atherosclerosis measures, significantly 
increases the predictive value for cardiovascular outcomes.61-64 
They also indicated that cfPWV aggregates information for 
the stratification of cardiovascular risk, with the potential for 
clinical applicability. The use of cfPWV allowed to reclassify 
the cardiovascular risk range of the individuals and was able 
to improve the evaluation of the prognosis of cardiovascular 
risk in 10 years in individuals with intermediate risk by 13%, 
according to a recent systematic review.59,65 Thus, the presence 
of an elevated cfPWV measurement added to classic risk 
factors indicates an excess of cardiovascular risk and suggests 
the need for a more rigorous multifactorial approach.
Role of central aortic pressure as a predictor of 
cardiovascular outcomes
One of the first publications to draw the attention of the 
scientific community to the role of central aortic pressure 
in cardiovascular outcomes, regardless of the peripheral BP 
values, was the Conduit Artery Function Evaluation (CAFE) 
study in 2006. In this analysis, the hypertensive patients who 
presented a greater reduction of the systolic component of 
the central aortic pressure to the same level of reduction of 
the BP values  obtained by the conventional evaluation had 
a lower incidence of cardiovascular outcomes.66 In that same 
year, the European Society of Cardiology published a position 
drawing attention to the fact that brachial measurements 
overestimate the central BP values  and that the systolic 
component of central aortic pressure, as well as central pulse 
pressure, are better predictors of cardiovascular outcomes, 
especially in patients with hypertension and chronic kidney 
disease.37 Other publications have also drawn attention to 
this superiority when comparing central measurements with 
brachial ones obtained from ambulatory BP monitoring 
(ABPM).67 On the other hand, a meta-analysis of 11 
longitudinal studies showed that both central aortic systolic 
pressure and central pulse pressure were independent 
markers of outcome and cardiovascular mortality, but 
were not superior to the values  obtained by conventional 
measurement (peripheral pressure assessment, p = 0.057).21 
Relationship of central parameters with 
target-organ lesions and associated 
clinical conditions
Numerous studies have demonstrated that central BP 
measurement is promising in terms of better correlation 
with cardiovascular events.68 Differences in central and 
peripheral arterial pulsatility are difficult to be attributed to 
cardiovascular events.69 No studies have so far demonstrated 
robust evidence that central BP adds a new model of 
cardiovascular risk stratification in relation to the conventional 
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SBP and DBP measurement. A recent analysis of data from 
the Framingham Offspring Cohort70 demonstrated a strong 
correlation between central aortic pressure and the incidence 
of cardiovascular events. A follow-up of up to 6.8 years in a 
population of 2,492 individuals (mean age 66 ± 9 years) has 
shown that 6% had a cardiovascular event. In a multivariate 
analysis, the measurement of central aortic pressure in this 
population correlated significantly with cardiovascular events. 
The CAFE study66 recruited 2,199 patients from the five 
centers of the ASCOT study and performed tonometry by 
radial artery applanation for analysis of central BP and pulse 
wave. Although the two arms of the study presented similar 
brachial pressure reduction (difference of 0.7 mmHg, 95%CI 
0.4 – 1.7, p = 0.2), there was a reduction in central aortic 
pressure with statistical significance in the group that used 
amlodipine (central aortic systolic pressure 4.3 mmHg, 95%CI 
3.3 – 5.4, p < 0.0001; and central aortic pulse pressure 3.0 
mmHg, 95%CI 2.1 – 3.9, p < 0.0001). A post hoc analysis 
of this study demonstrated that central BP was significantly 
associated with combined cardiovascular outcomes and the 
development of renal failure (p < 0.05). 
Implication of the central parameters in the 
strategy for the treatment of hypertension
Despite the adequate reduction of (peripheral) BP with 
anti-hypertensive treatment, the results on clinical outcomes 
have shown a significant difference attributed to the pleiotropic 
effects of anti-hypertensive drugs on the elastic properties of 
large arteries (aorta), on the central aortic pressure, and on 
the cfPWV.71 Table 3 shows the effects of different classes of 
anti-hypertensive drugs on central hemodynamics.
Beta-blockers
The CAFE study compared the effect of beta-blockers on the 
central pressure for a similar peripheral BP, and the atenolol/
thiazide group showed higher aortic central pressure values 
when compared with the amlodipine/perindopril group.66 
Nebivolol (a beta-blocker with a vasodilatory effect) and 
carvedilol (an anti-hypertensive with alpha- and beta-blocking 
effects) compared with atenolol promoted a greater reduction 
in central aortic pressure and pulse amplification.72,73 Nebivolol 
reduces central aortic pressure and the augmentation index 
in mildly hypertensive patients after 3 months of treatment.74
Calcium channel blockers
Calcium channel blockers reduce oxidative stress in 
experimental models and decrease central aortic pressure.66 
The AORTA study compared the addition of azelnidipine or 
amlodipine to hypertensive patients using olmesartan and 
demonstrated that the azelnidipine group achieved a greater 
reduction in central aortic pressure and in the augmentation 
index, and a greater regression in left ventricular hypertrophy 
and left ventricular diastolic dysfunction.75,76
Angiotensin converting enzyme inhibitors
The reduction in central aortic pressure demonstrated 
in comparative studies with angiotensin converting enzyme 
inhibitors (ACEi) can be attributed to possible mechanisms 
involving reduction in compliance and oxidative stress, 
structural remodeling of the vascular wall, collagen/elastin 
relationship, anti-inflammatory effect and consequent 
relaxation of the vascular smooth muscle.77,78
Angiotensin II AT1 receptor blockers
Valsartan and captopril reduce to a similar extent the 
central aortic pressure and the cfPWV.79 The EXPLOR 
study compared valsartan/amlodipine versus amlodipine/
atenolol for a similar BP reduction in the peripheral artery. 
Central aortic pressure and cfPWV showed a greater 
reduction in the valsartan/amlodipine group.80 Studies with 
other AT1 receptor blockers have shown similar results.81,82
Diuretics
Diuretics appear to have no beneficial effect on central 
hemodynamics.83,84 
Nitrates 
The effects of nitrates on central aortic pressure are 
attributed to the relaxation of the vascular smooth muscle 
of medium-caliber arteries that result in a reduction in 
the reflection wave amplitude, a reduction in the pulse 
Table 3 – Comparative effect of different classes of anti-hypertensive drugs on central hemodynamics
Classes of anti-hypertensive drugs CSaP CDaP Amplification Reflection cfPWV PAP 
Beta-blockers      
Calcium channel blockers  /    
Angiotensin-converting enzyme inhibitors      
Angiotensin II AT1 receptor blockers  / /   
Diuretics   /   
Nitrates      /
CSaP: central systolic aortic pressure; CDaP: central diastolic aortic pressure; cfPWV: carotid-femoral pulse wave velocity; PAP: peripheral arterial pressure.
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wave velocity, and an increase in the effective reflection 
distance. Isosorbide mononitrate has also been evaluated in 
hypertensive patients and demonstrated a greater reduction 
in central aortic pressure than in peripheral BP and a greater 
reduction in the augmentation index without a significant 
change in the heart rate. On the other hand, nitrates do not 
influence cfPWV. 
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